<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944511</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1, mixed chimerism</org_study_id>
    <nct_id>NCT04944511</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody Improve Mixed Chimerism</brief_title>
  <acronym>HLH</acronym>
  <official_title>PD-1 Antibody Improve Mixed Chimerism in Patients With Hemophagocytic Lymphohistiocytosis After Allo-HCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific&#xD;
      CD8+T cells, thus matter a lot in immune escape. We intend to use PD-1 antibody to improve&#xD;
      the function of lymhocyte and improve the chimerism in patients after allo-HCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mixed chimerism is a trouble condition after allogeneic hematopoietic cell transplantation&#xD;
      (Allo-HCT),all targeted treatment are aimed to improve the function of lymphocyte recipient.&#xD;
      PD-1 antibody was reported to restored the function of impaired lymphocyte. Therefore, we&#xD;
      want to use PD-1 antibody to improve the function of lymhocyte and improve the chimerism in&#xD;
      HLH patients after allo-HCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>one group of HLH patients with mixed chimerism (80%-95%), PD-1 antibody will be used to improve the chimerism</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chimeric rate</measure>
    <time_frame>4 weeks after toripalimab injection was used</time_frame>
    <description>Chimeric rate in bone marrow or peripheral blood of HLH patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events as assessed by CTCAE v5.0；</measure>
    <time_frame>every 2 weeks after intervention, until 8 weeks after the use of PD-1 antibody</time_frame>
    <description>Adverse events including thyroid function，liver function damage, myelosuppression, infection, bleeding and so on.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>From enrollment until death or the end of the experiment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PD-1 Antibody</condition>
  <condition>Mixed Chimerism</condition>
  <arm_group>
    <arm_group_label>PD-1 antibody for mixed chimerism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab Injection</intervention_name>
    <description>Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.</description>
    <arm_group_label>PD-1 antibody for mixed chimerism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. EBV-HLH according to the HLH-04 diagnostic criteria.&#xD;
&#xD;
          2. After allo-HCT, have achieved engraftment and reconstitute of hematopoiesis. have&#xD;
             achieved full donor chimerism.&#xD;
&#xD;
          3. Withdraw immunosuppressive agent, chimeric rate was 80%-95%&#xD;
&#xD;
          4. Age &gt;18 years old, gender is not limited.&#xD;
&#xD;
          5. no graft-versus-host disease was observed.&#xD;
&#xD;
          6. No secondary graft failure (ANC &lt;0.5*10^9/l,PLT &lt;10*10^9/l)&#xD;
&#xD;
          7. Before the start of the study, aminopherase (ALT/AST) and total bilirubin were normal.&#xD;
             Serum creatinine ≤ 1.5 times the upper limit of Normal (ULN); No thyroid dysfunction.&#xD;
             The left ventricular ejection fraction (LVEF) was normal.&#xD;
&#xD;
          8. Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to the test drug ingredients or to a more severe allergic constitution.&#xD;
&#xD;
          2. Chimeric rate continue to decline after 2 weeks of toripalimab Injection used.&#xD;
&#xD;
          3. Serious immunoreaction: myocardial damage, hepatitis, pneumonia.&#xD;
&#xD;
          4. Central nervous system symptoms.&#xD;
&#xD;
          5. Serious mental illness.&#xD;
&#xD;
          6. Active bleeding of the internal organs&#xD;
&#xD;
          7. Uncontrollable infection；&#xD;
&#xD;
          8. Pancreatitis history. Patients unable to comply during the trial and/or follow-up&#xD;
             phase;&#xD;
&#xD;
          9. Participate in other clinical research at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Wang</last_name>
    <phone>86-010-63139862</phone>
    <email>wangzhao@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yahong You</last_name>
    <phone>17810283962</phone>
    <email>15332022659@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Chimerism</keyword>
  <keyword>PD-1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

